Stay updated on Durvalumab and Pexidartinib in Pancreatic/Colorectal Clinical Trial
Sign up to get notified when there's something new on the Durvalumab and Pexidartinib in Pancreatic/Colorectal Clinical Trial page.

Latest updates to the Durvalumab and Pexidartinib in Pancreatic/Colorectal Clinical Trial page
- Check3 days agoChange DetectedThe footer’s site revision number changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check10 days agoChange DetectedThe study record page displays a 403 Forbidden message and a Home link instead of study details.SummaryDifference0.5%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study details, with a minimal navigation header indicating an access issue. This reflects restricted access rather than a content update.SummaryDifference18%

- Check45 days agoChange DetectedAn NIH grant/contract attribution for 2015 was added, and the page revision text was updated from v3.6.5 to v3.6.6, reflecting a minor version update in the page’s metadata.SummaryDifference0.1%

- Check66 days agoChange DetectedThe page's revision tag updated from v3.6.4 to v3.6.5, indicating a new version of the page.SummaryDifference0.1%

- Check81 days agoChange DetectedRevision updated from v3.6.3 to v3.6.4, indicating a minor update to the page's backend or UI. The study content appears unchanged.SummaryDifference0.1%

Stay in the know with updates to Durvalumab and Pexidartinib in Pancreatic/Colorectal Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab and Pexidartinib in Pancreatic/Colorectal Clinical Trial page.